Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Yale University

www.yale.edu

Latest From Biosynexus Inc.

Last line of defence crumbling: WHO report on global antimicrobial resistance

Drug resistance to carbapenem antibiotics, which are used as a last-resort for treating hospital acquired bacterial infections caused by Klebsiella pneumoniae, such as pneumonia, bloodstream infections and infections in newborns, has spread to all regions of the world. This is the key finding by the World Health Organization (WHO) in its first ever report on antimicrobial resistance globally.

Infectious Diseases Gynecology & Urology

Altor BioScience Corp.

Altor BioSciences aims to exploit the intrinsic selectivity of T-cell receptors (TCRs) by pairing soluble receptors with therapeutic payloads. These TCR/drug combos are smaller than antibodies and could theoretically bind to targets within cells, not just on the cell surface, a main selling point of the firm's so-called STAR technology. At first Altor plans to enhance the safety and efficacy of existing marketed drugs by pairing them with monoclonal antibody-like TCRs for improved targeting.
BioPharmaceutical

The Right Place and Time for Applied Molecular Evolution

Applied Molecular Evolution is a company seemingly in the right place, with the right technology, at the right time--a beneficiary of Big Pharma's current search for ways to short-cut the discovery process. In the last three months, AME received initial product development milestones from two deals and filed an IND on its own lead product candidate, an improved version of Remicade. Those events validated its technology for optimizing proteins-enough so that partner Eli Lilly decided to buy the firm outright.
BioPharmaceutical Business Strategies
See All
Advertisement
Advertisement
UsernamePublicRestriction

Register